Grant William B, Boucher Barbara J, Cheng Richard Z, Pludowski Pawel, Wimalawansa Sunil J
Sunlight, Nutrition, and Health Research Center, 1745 Pacific Ave., Ste. 504, San Francisco, CA 94109, USA.
The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Nutrients. 2025 Jun 25;17(13):2102. doi: 10.3390/nu17132102.
The role of vitamin D in reducing cardiovascular disease (CVD) risk remains debated despite growing evidence. Prospective observational studies consistently show that low serum 25-hydroxyvitamin D [25(OH)D] concentrations (below 40-50 nmol/L [16-20 ng/mL]) are associated with the highest risk of CVD incidence. In addition, a large prospective observational study found that serum 25(OH)D concentration was inversely correlated with CVD mortality rate to over 100 nmol/L. Randomized controlled trials have not generally demonstrated benefit due to faulty study designs, such as enrolling participants with baseline 25(OH)D levels > 50 nmol/L. However, a major trial found that 60,000 IU/month of vitamin D supplementation reduced the risk of major cardiovascular events for participants with predicted 25(OH)D concentrations ≥ 50 nmol/L or taking statins or CV drugs by ~13 to ~17%. In addition, vitamin D supplementation studies have found modest reductions in several CVD risk factors. Other observational studies of vitamin D supplementation have reported reduced CVD risks (e.g., ischemic heart disease, hypertension, and myocardial infarction). Temporal ecological studies further support this relationship, revealing that CVD incidence rates are lowest in summer and CVD mortality rates are significantly higher in late winter-when 25(OH)D concentrations are lowest-compared to late summer. A previously reported analysis using eight of Hill's criteria for causality in a biological system further strengthens the biological plausibility of vitamin D's role in CVD risk reduction. Its role in modulating inflammation and oxidative stress, improving endothelial function, and reducing several cardiometabolic risk factors supports its inclusion as part of a comprehensive, multi-modal approach to cardiovascular health. Therefore, vitamin D should be considered an integral component in the prevention and management of CVD. Preferably, it should be used in combination with other nutritional supplements, a heart-healthy diet, and prescription medications to reduce the risk of CVD incidence. People should consider vitamin D supplementation with at least 2000 IU/day (50 mcg/day) (more for those who are obese) when sun exposure is insufficient to maintain serum 25(OH)D concentrations above 75 nmol/L. To reduce CVD mortality rates, higher doses to achieve higher 25(OH)D concentrations might be warranted.
尽管证据越来越多,但维生素D在降低心血管疾病(CVD)风险方面的作用仍存在争议。前瞻性观察性研究一致表明,血清25-羟基维生素D [25(OH)D] 浓度低(低于40-50 nmol/L [16-20 ng/mL])与CVD发病风险最高相关。此外,一项大型前瞻性观察性研究发现,血清25(OH)D浓度与CVD死亡率呈负相关,直至超过100 nmol/L。由于研究设计存在缺陷,如纳入基线25(OH)D水平>50 nmol/L的参与者,随机对照试验一般未证明有获益。然而,一项主要试验发现,每月补充60000 IU维生素D可使预测25(OH)D浓度≥50 nmol/L或正在服用他汀类药物或心血管药物的参与者发生主要心血管事件的风险降低约13%至17%。此外,维生素D补充研究发现,一些心血管疾病风险因素有适度降低。其他维生素D补充的观察性研究报告称心血管疾病风险降低(如缺血性心脏病、高血压和心肌梗死)。时间生态学研究进一步支持了这种关系,表明夏季CVD发病率最低,与夏末相比,冬末(此时25(OH)D浓度最低)CVD死亡率显著更高。先前一项使用希尔生物系统因果关系标准中的八条标准进行的分析进一步加强了维生素D在降低CVD风险中作用的生物学合理性。其在调节炎症和氧化应激、改善内皮功能以及降低多种心脏代谢风险因素方面的作用支持将其纳入心血管健康综合多模式方法的一部分。因此,维生素D应被视为CVD预防和管理的一个组成部分。最好将其与其他营养补充剂、有益心脏健康的饮食和处方药联合使用,以降低CVD发病风险。当阳光照射不足以维持血清25(OH)D浓度高于75 nmol/L时,人们应考虑每天补充至少2000 IU(50 mcg/天)维生素D(肥胖者剂量更高)。为降低CVD死亡率,可能需要更高剂量以达到更高的25(OH)D浓度。